INTRODUCTION: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a disorder of oxidation of long chain fat, and can present as cardiomyopathy or fasting intolerance in the first months to years of life, or as myopathy in later childhood to adulthood. Expanded newborn screening has identified a relatively high incidence of this disorder (1:31,500), but there is a dearth of evidence-based outcomes data to guide the development of clinical practice protocols. This consensus protocol is intended to assist clinicians in the diagnosis and management of screen-positive newborns for VLCAD deficiency until evidence-based guidelines are available. METHOD: The Oxford Centre for Evidence-based Medicine system was used to grade the literature review and create recommendations graded from A (evidence level of randomized clinical trials) to D (expert opinion). Delphi was used as the consensus tool. A panel of 14 experts (including clinicians, diagnostic laboratory directors and researchers) completed three rounds of survey questions and had a face-to-face meeting. RESULT: Panelists reviewed the initial evaluation of the screen-positive infant, diagnostic testing and management of diagnosed patients. Grade C and D consensus recommendations were made in each of these three areas. The panel did not reach consensus on all issues, particularly in the dietary management of asymptomatic infants diagnosed by newborn screening.
INTRODUCTION: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a disorder of oxidation of long chain fat, and can present as cardiomyopathy or fasting intolerance in the first months to years of life, or as myopathy in later childhood to adulthood. Expanded newborn screening has identified a relatively high incidence of this disorder (1:31,500), but there is a dearth of evidence-based outcomes data to guide the development of clinical practice protocols. This consensus protocol is intended to assist clinicians in the diagnosis and management of screen-positive newborns for VLCAD deficiency until evidence-based guidelines are available. METHOD: The Oxford Centre for Evidence-based Medicine system was used to grade the literature review and create recommendations graded from A (evidence level of randomized clinical trials) to D (expert opinion). Delphi was used as the consensus tool. A panel of 14 experts (including clinicians, diagnostic laboratory directors and researchers) completed three rounds of survey questions and had a face-to-face meeting. RESULT: Panelists reviewed the initial evaluation of the screen-positive infant, diagnostic testing and management of diagnosed patients. Grade C and D consensus recommendations were made in each of these three areas. The panel did not reach consensus on all issues, particularly in the dietary management of asymptomatic infants diagnosed by newborn screening.
Authors: T H Zytkovicz; E F Fitzgerald; D Marsden; C A Larson; V E Shih; D M Johnson; A W Strauss; A M Comeau; R B Eaton; G F Grady Journal: Clin Chem Date: 2001-11 Impact factor: 8.327
Authors: Ute Spiekerkoetter; Bin Sun; Thomas Zytkovicz; Ronald Wanders; Arnold W Strauss; Udo Wendel Journal: J Pediatr Date: 2003-09 Impact factor: 4.406
Authors: Georgianne L Arnold; Dwight D Koeberl; Dietrich Matern; Bruce Barshop; Nancy Braverman; Barbara Burton; Stephen Cederbaum; Annette Fiegenbaum; Cheryl Garganta; James Gibson; Stephen I Goodman; Cary Harding; Stephen Kahler; David Kronn; Nicola Longo Journal: Mol Genet Metab Date: 2007-12-21 Impact factor: 4.797
Authors: U Spiekerkoetter; C Tokunaga; U Wendel; E Mayatepek; V Exil; M Duran; F A Wijburg; R J A Wanders; A W Strauss Journal: Eur J Clin Invest Date: 2004-03 Impact factor: 4.686
Authors: Beth K Potter; Julian Little; Pranesh Chakraborty; Jonathan B Kronick; Jessica Evans; Julia Frei; Sarah C Sutherland; Kumanan Wilson; Brenda J Wilson Journal: J Inherit Metab Dis Date: 2011-06-01 Impact factor: 4.982
Authors: Marcus J Miller; Lindsay C Burrage; James B Gibson; Meghan E Strenk; Edward J Lose; David P Bick; Sarah H Elsea; V Reid Sutton; Qin Sun; Brett H Graham; William J Craigen; Victor Wei Zhang; Lee-Jun C Wong Journal: Mol Genet Metab Date: 2015-09-02 Impact factor: 4.797
Authors: F Fatehi; A A Okhovat; Y Nilipour; M Mroczek; V Straub; A Töpf; A Palibrk; S Peric; V Rakocevic Stojanovic; H Najmabadi; S Nafissi Journal: Eur J Neurol Date: 2020-07-24 Impact factor: 6.089
Authors: Marta Sousa Moniz; Maria Inês Mascarenhas; Carlos Escobar; Pedro Nunes; Clara Abadesso; Helena Loureiro; Helena Almeida Journal: Rev Bras Ter Intensiva Date: 2017 Jan-Mar
Authors: Frank ter Veld; Martina Mueller; Simone Kramer; Ulrike Haussmann; Diran Herebian; Ertan Mayatepek; Maurice D Laryea; Sonja Primassin; Ute Spiekerkoetter Journal: PLoS One Date: 2009-07-30 Impact factor: 3.240